Retia Medical
Retia Medical is a private medical device company that develops and sells the FDA-cleared Argos Cardiac Output Monitor and Argos Infinity software platform, both powered by its proprietary Multi-Beat Analysis (MBA) algorithm for hemodynamic monitoring of surgical and critically ill patients in hospital ORs, ICUs, and tele-ICU environments.
- Company typePrivate
- Founded2012
- HeadquartersWhite Plains, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Retia Medical does
Retia Medical is a private medical device company founded in 2011-2012 that develops and sells software and hardware for hemodynamic (cardiovascular) monitoring in hospital operating rooms, intensive care units, and tele-ICU environments. The company's core technology is the proprietary Multi-Beat Analysis (MBA) algorithm, originally developed at Michigan State University and MIT and exclusively licensed to Retia, which analyzes multiple heartbeats from arterial blood pressure waveforms to derive continuous cardiac output and related parameters. The algorithm is protected by 12-15 issued and pending patents and validated in 14 peer-reviewed clinical studies demonstrating 50% greater accuracy than older single-beat approaches and superior performance in challenging clinical scenarios including arrhythmia, cardiogenic shock, and low-flow states.
Retia's product portfolio consists of two FDA 510(k)-cleared offerings: the Argos Cardiac Output Monitor, a bedside hardware device delivering 10 hemodynamic parameters via a single reusable cable with no proprietary disposables; and Argos Infinity, a software platform cleared in February 2026 that extends the MBA algorithm across hospital systems by running on top of existing monitoring and tele-ICU infrastructure. The company monetizes primarily through capital equipment sales and software licensing, supported by an exclusive US distribution agreement with Medtronic (expanded to Western Europe in June 2026), a national group purchasing agreement with Premier, Inc. covering approximately 4,400 US hospitals, and partnerships with JANZ Corporation for military facilities and CTI for specialty distribution. The company has raised approximately $22.15 million in total funding, most recently a $15 million Series B led by Fresenius Medical Care Ventures in July 2022, and reports a sixfold revenue increase over the two-year period ending Q1 2026.
Retia Medical firmographics
Firmographics- Name
- Retia Medical
- Legal name
- Retia Medical Systems, Inc.
- Website
- https://retiamedical.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Retia Medical is a private medical device company that develops and sells the FDA-cleared Argos Cardiac Output Monitor and Argos Infinity software platform, both powered by its proprietary Multi-Beat Analysis (MBA) algorithm for hemodynamic monitoring of surgical and critically ill patients in hospital ORs, ICUs, and tele-ICU environments.
- Ownership category
- akta.pro rank
Retia Medical industry classification
Industry- Product category
- Hemodynamic Monitoring Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industry
- Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous) (HLAHACAA)
Keywords
Where Retia Medical is headquartered
LocationHeadquarters
- HQ city
- White Plains
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Retia Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Argos Cardiac Output Monitor Hardware Sales: Capital equipment sales of Argos hemodynamic monitors to hospitals. One-time hardware purchase with no per-patient disposable costs, enabling broader deployment across ICU beds without incremental variable costs.
- Argos Infinity Software Platform: Software licensing for cardiovascular intelligence platform deployed across hospital monitoring infrastructure. Operates on top of existing tele-ICU and bedside monitoring systems.
- Algorithm Licensing: MBA algorithm technology licensed for integration into other monitoring platforms and medical devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Low fixed capital cost with no disposables |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels7 records
Retia Medical product offering
Product offeringCore offering
Retia Medical develops, manufactures, and sells the Argos Cardiac Output Monitor and Argos Infinity cardiovascular intelligence software platform, both powered by the proprietary Multi-Beat Analysis (MBA) algorithm. The Argos Monitor is an FDA-cleared bedside hemodynamic monitor that analyzes arterial blood pressure waveforms to deliver 10 hemodynamic parameters in OR and ICU settings, while Argos Infinity extends the same algorithm to enterprise-wide surveillance across hospital and tele-ICU infrastructure. Both products are sold to hospitals and health systems and are designed to function without proprietary disposables.
Product overview
Retia Medical offers a portfolio of cardiovascular intelligence products centered on its proprietary Multi-Beat Analysis (MBA) algorithm. The core offerings consist of two FDA-cleared products: the Argos Cardiac Output Monitor (bedside hemodynamic monitoring device) and Argos Infinity (enterprise software platform). The Argos Monitor provides point-of-care cardiovascular intelligence in OR and ICU settings with no proprietary disposables, while Argos Infinity extends the same validated algorithm across hospital systems via existing monitoring infrastructure. Both products are powered by the MBA algorithm, which analyzes arterial waveforms over multiple heartbeats to deliver consistent accuracy in challenging clinical scenarios.
Differentiator
Problem solved
Functional benefit
Brands
- Argos: FDA-cleared cardiac output monitor featuring Multi-Beat Analysis algorithm for hemodynamic monitoring in OR and ICU settings
- Argos Infinity
- Multi-Beat Analysis (MBA)
Products and services
- Argos Cardiac Output Monitor FDA-cleared hemodynamic monitor for bedside cardiovascular intelligence in OR and ICU settings. Provides 10 hemodynamic parameters (CO, CI, SV, SVI, SVR, SVRI, HR, BP, MAP, PPV) using the Multi-Beat Analysis (MBA) algorithm. Connects to a patient's existing arterial line via a single reusable cable, requires no calibration, and uses no proprietary disposables. For anesthesiologists, intensivists, and critical care teams in hospitals.
- Argos Infinity FDA-cleared cardiovascular intelligence software platform that operates on top of existing hospital monitoring and tele-ICU infrastructure to analyze real-time physiologic data streams and deliver enterprise-wide cardiovascular surveillance across multiple beds, units, and health systems. Designed for digital care environments including tele-ICUs and digital ORs, enabling centralized surveillance and analytics.
- Multi-Beat Analysis (MBA) Algorithm (Licensing) Proprietary algorithm licensed for integration into other monitoring platforms and medical devices. Analyzes multiple heartbeats from blood pressure waveforms to model patient vascular resistance directly, providing 50% greater accuracy than older single-beat algorithms and validated in 14 peer-reviewed clinical publications across diverse patient populations including arrhythmia, cardiogenic shock, and low-flow states.
Quantifiable outcome
- 50% reduction in complications with hemodynamic-guided care
- +5 more outcomes
Companies that use Retia Medical
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
Retia Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability3 records
Feature4 records
Retia Medical partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, major and minor.
- Medtronic Western EuropecoreExpansion of commercial relationship to distribute Argos Cardiac Output Monitor across Western Europe. Represents Retia's first entry into European markets, reaching one of the world's most important critical care markets through Medtronic's established distribution network.
- MedtroniccoreExclusive US distribution agreement for Argos Cardiac Output Monitor. Medtronic distributes through their Acute Care & Monitoring business. Expanded to include Western Europe distribution in 2026. Medtronic's INVOS cerebral oximetry technology complements Argos for comprehensive patient insights.
- Premier, Inc.majorNational group purchasing agreement for Hemodynamic Monitoring Products. Premier members can access pre-negotiated special pricing and terms. Premier serves approximately 4,400 U.S. hospitals and 250,000 continuum of care providers.
- JANZ CorporationmajorStrategic partnership with Service-Disabled Veteran Owned Small Business serving U.S. Government hospital to home market. Expands availability of Argos Monitor to military healthcare facilities worldwide.
- Capsule TechnologiesmajorFirst company to utilize Capsule's new Device Driver Interface development strategy for Argos Cardiac Monitor integration. Uses IHE-PCD framework for rapid device connectivity, EMR interoperability, and patient safety through rapid identification. Supports RTM terminology mapping and IHE Patient Demographics Query.
- CTI (Clinical Technology, Inc.)minorPartnership with specialty medical distributor based in Cleveland, Ohio for broad US market coverage. CTI provides marketing and clinical sales support to help expand nationally.
- Michigan State UniversitycoreTechnology licensor for Multi-Beat Analysis algorithm developed by Dr. Ramakrishna Mukkamala. Exclusive licensing of cardiovascular signal processing technology. Also invested through Red Cedar Ventures.
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
Retia Medical competitors and assessment
Company assessmentBroad incumbents
- Dräger: Dräger's Infinity and Perseus monitoring platforms are major European-installed bases for ICU and OR monitoring. With Retia's Medtronic Western Europe launch, Dräger is a key incumbent competitor in the same European accounts.
- GE HealthCare: GE HealthCare's CARESCAPE patient monitoring portfolio is broadly deployed across US hospitals and integrates hemodynamic parameters alongside multi-parameter monitoring — an incumbent ecosystem against which Retia's MBA-driven add-on competes for ICU bed share.
- Philips: Philips IntelliVue and Patient Monitoring portfolio is widely installed across hospitals; Retia's Argos integrates with Philips bedside monitors via interface cables, making Philips both a channel partner and an incumbent competitor for advanced hemodynamic insight.
- Nihon Kohden: Nihon Kohden's bedside monitoring portfolio competes broadly for ICU/OR hemodynamic monitoring share; Retia offers an interface cable for Nihon Kohden monitors, indicating both overlap and integration in the same hospital ecosystem.
- Spacelabs Healthcare: Spacelabs (now part of OSI Systems) provides patient monitoring and is one of the supported integration partners for Retia's Argos Monitor, making it both a partner ecosystem participant and broad incumbent competitor in US hospital monitoring.
- Mindray: Mindray's multi-parameter patient monitors are widely deployed globally; Argos integrates with Mindray monitors via interface cables, and Mindray represents both a partner and broad incumbent competitor in the same hemodynamic monitoring space.
Direct peers
- Edwards Lifesciences: Edwards Lifesciences' FloTrac/Vigileo and ClearSight systems are the dominant minimally invasive and non-invasive cardiac output monitors in US ORs and ICUs. Directly competes with Retia's Argos Monitor on the same hemodynamic-parameter use cases and clinical stakeholder relationships.
- Masimo (LiDCO): Masimo acquired LiDCO, a minimally invasive cardiac output monitoring technology, and integrates hemodynamic parameters into its root patient monitoring platform — directly competitive with Retia's MBA-based Argos system in the same OR/ICU channel.
- Baxter International (Cheetah Medical / Starling SV): Baxter acquired Cheetah Medical, maker of the Starling SV non-invasive cardiac output monitor, which competes head-to-head with Retia's non-invasive MBA-based offering in ICU hemodynamic management.
Emerging players
- Osypka Medical: Osypka Medical is a niche European developer of invasive and non-invasive cardiac output monitoring devices; smaller and more regional than Retia but directly competing on the same hemodynamic monitoring use cases in cardiac surgery and ICU.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Retia Medical social profiles
Digital presenceRetia Medical compliance and trust
Trust signalCompliance3 records
Retia Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Retia Medical leadership team
Management profileNumber of profiles
Profiles6 records
Retia Medical funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Retia Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Retia Medical
What does Retia Medical do?
Retia Medical develops, manufactures, and sells the Argos Cardiac Output Monitor and Argos Infinity cardiovascular intelligence software platform, both powered by the proprietary Multi-Beat Analysis (MBA) algorithm. The Argos Monitor is an FDA-cleared bedside hemodynamic monitor that analyzes arterial blood pressure waveforms to deliver 10 hemodynamic parameters in OR and ICU settings, while Argos Infinity extends the same algorithm to enterprise-wide surveillance across hospital and tele-ICU infrastructure. Both products are sold to hospitals and health systems and are designed to function without proprietary disposables.
Is Retia Medical a public or private company?
Retia Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Retia Medical founded?
Retia Medical was founded in 2012. It employs 11 to 50 people.
Where is Retia Medical based?
Retia Medical is headquartered in White Plains, United States, in the North America region.
How does Retia Medical make money?
Three revenue lines are on record. Argos Cardiac Output Monitor Hardware Sales are the primary driver. The others are argos Infinity Software Platform and algorithm Licensing.
Who are Retia Medical's main competitors?
Broad incumbents on record are Dräger, GE HealthCare, Philips, Nihon Kohden, Spacelabs Healthcare and Mindray. Direct peers are Edwards Lifesciences, Masimo (LiDCO) and Baxter International (Cheetah Medical / Starling SV). Osypka Medical is listed as an emerging player.
Does Retia Medical have an API?
No public API is recorded for Retia Medical.
What industry is Retia Medical in?
Retia Medical's product category is Hemodynamic Monitoring Systems. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAHACAA, Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous). Its NAICS code is 334510 and its SIC code is 3845.